Market Views – Page 35 – media

Positive outlook for biotech M&A and funding, says report

A report examining the European venture landscape for health and biotech firms over the first half of 2017 has found that there is a continuing positive environment for venture funding and M&A in the sector.
- Source: news.open-medical
- 438
- August 11, 2017
health M&A Market Views
Roche out-licneses lebrikizumab to Dermira

Roche has agreed to out-license certain rights to its invesitgational atropic dermatitis drug lebrikizumab to Demira in a deal that could be worth more than $1.4 billion.
- Source: pharmatimes
- 454
- August 10, 2017
Company Insight dermatitis Dermira lebrikizumab Market Views
FDA extends review on Dynavax’s Heplisav-B

FDA extends review on Dynavax's hepatitis B vaccine candidate Heplisav-B, but both management and analysts said they remain confident in approval.
- Source: fiercepharm
- 632
- August 7, 2017
Company Insight FDA hepatitis Heplisav-B Market Views vaccine
CombiMatrix, Skyline Medical, Victory Square Technologies

The merger and acquisition information of CombiMatrix, Skyline Medical and Victory Square Technologies.
- Source: medicaldevices-network.com
- 392
- August 7, 2017
Company Insight M&A Market Views
Diabetes prescriptions rocket 80 percent in a decade

Growth in prescriptions for diabetes medicines is exceeding the rise in overall prescribing, according to new figures from NHS Digital.
- Source: pharmatimes
- 563
- August 3, 2017
diabetes Market Views Researches
Emergent secures $23m to develop new auto-injector for US’ DoD

US-based life sciences firm Emergent BioSolutions has secured around $23m for the development of a new multi-drug auto-injector to deliver nerve agent antidote.
- Source: medicaldevice-network.com
- 433
- August 2, 2017
antidote FDA Market Views
Cardinal buys Medtronic’s Patient Recovery business for $6.1bn

Cardinal Health has concluded the purchase of Patient Care, Deep Vein Thrombosis and Nutritional Insufficiency business from Medtronic for a total of $6.1bn.
- Source: Medicaldevices-network.com
- 499
- August 1, 2017
Company Insight Market Views patient care
AZ, Merck link to develop and commercialise cancer drugs

AstraZeneca and Merck & Co have announced a global strategic oncology collaboration to co-develop and co-commercialise the former’s Lynparza and selumetinib for multiple cancer types.
- Source: pharmatimes
- 500
- July 31, 2017
cancer Lynparza Market Views Researches therapy
Tentative US approval for Merck’s diabetes therapy

The US Food and Drug Administration has given a tentative green light to Merck & Co’s follow-on biologic basal insulin Lusduna Nexvue.
- Source: pharmatimes
- 480
- July 21, 2017
Company Insight diabetes Lusduna Nexvue Market Views
Sanofi, Ablynx sign $2.7bn research, licensing pact

Sanofi has signed a research pact and licensing deal with Ablynx that could bring as much as $2.7 billion euros to the Belgian biotech’s coffers if all targets are met.
- Source: pharmatimes
- 515
- July 21, 2017
Company Insight Market Views Sanofi Ablynx

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.